How have ZTS shares performed this year?

Zoetis' stock was trading at $197.37 on January 1st, 2024. Since then, ZTS stock has decreased by 8.9% and is now trading at $179.84. View the best growth stocks for 2024 here .

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, May, 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm's quarterly revenue was up 9.5% compared to the same quarter last year. Read the conference call transcript .

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com . Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Does Zoetis have any subsidiaries?

Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and others.

Who are Zoetis' major shareholders?

Top institutional investors of Zoetis include Bank of New York Mellon Corp (1.03%), Banque Pictet & Cie SA (0.54%), Sarasin & Partners LLP (0.49%) and Swedbank AB (0.43%). Insiders that own company stock include Kristin C Peck , Heidi C Chen , Roxanne Lagano , Willie M Reed , Robert J Polzer , Glenn David , Roman Trawicki and Gregory Norden . View institutional ownership trends .

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Hawkins (HWKN) , Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH) .

NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$179.84

-0.92 (-0.51%)

(As of 07/26/2024 ET)

Compare

Today's Range: $179.26
▼
$183.85
50-Day Range: $167.92
▼
$183.08
52-Week Range: $144.80
▼
$201.92

Volume: 2.43 million shs
Average Volume: 2.83 million shs
Market Capitalization: $82.06 billion

P/E Ratio: 34.65
Dividend Yield: 0.96%
Price Target: $212.67

Get Zoetis alerts:

Zoetis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 18.3% Upside
$212.67 Price Target
Short Interest: Healthy
1.16% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.78
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 9.72%
From $5.76 to $6.32 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.61 out of 5 stars

Medical Sector

85th out of 936 stocks

Pharmaceutical Preparations Industry

29th out of 436 stocks

2.5

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zoetis has only been the subject of 4 research reports in the past 90 days.
Read more about Zoetis' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
1.16% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently decreased by 15.20%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.96%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 13 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 27.37% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
Read more about Zoetis' dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

3.2

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Zoetis this week, compared to 11 articles on an average week.
Search Interest
Only 15 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.
MarketBeat Follows
13 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.16% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Zoetis' insider trading history.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 9.72% in the coming year, from $5.76 to $6.32 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 34.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 34.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.79. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 16.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Zoetis' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZTS Stock News Headlines

July 25 at 8:35 AM | markets.businessinsider.com

Deep Dive Into Zoetis Stock: Analyst Perspectives (4 Ratings)

July 25 at 7:24 AM | americanbankingnews.com

Zoetis (NYSE:ZTS) Coverage Initiated at BTIG Research

July 26, 2024 | Unstoppable Prosperity (Ad)

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

July 23 at 8:13 PM | markets.businessinsider.com

Buy Rating Affirmed for Zoetis Amidst Favorable Market Dynamics and Strong Growth Potential

July 23 at 1:27 AM | americanbankingnews.com

Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of "Buy" by Analysts

July 16, 2024 | americanbankingnews.com

Zoetis Inc. (ZTS) to Issue Quarterly Dividend of $0.43 on September 4th

July 12, 2024 | investorplace.com

The Top 3 Long-Term Stocks to Buy for Decades of Gains

July 11, 2024 | globenewswire.com

Australia Veterinary Pharmaceutical Manufacturing Industry Market Research Report 2024 Featuring Virbac, Zoetis, and Intervet Schering-Plough Animal Health

July 26, 2024 | Unstoppable Prosperity (Ad)

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

July 8, 2024 | investorplace.com

3 Pet Stocks That Are Better Buys Than Chewy

July 8, 2024 | seekingalpha.com

Zoetis Deep Dive: Better Setup Than Human Pharma

July 4, 2024 | seekingalpha.com

Zoetis: Still A High Quality Business Led By Companion Animal Growth

July 3, 2024 | seekingalpha.com

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

June 26, 2024 | businesswire.com

Zoetis Foundation and Zoetis Deepen Commitment to Global Disaster Relief with American Red Cross and American Humane

June 15, 2024 | insidermonkey.com

Zoetis Inc. (ZTS): Did this Feminist Stock Soar High in Q1?

June 11, 2024 | seekingalpha.com

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

June 7, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS

June 7, 2024 | gurufocus.com

Zoetis Inc (ZTS)'s Winning Formula: Financial Metrics and Competitive Strengths

See More Headlines

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/4 Dividend: 4/18/2024
Last Earnings: 5/02/2024
Dividend Payable: 6/04/2024
Ex-Dividend for 9/4 Dividend: 7/18/2024
Today: 7/26/2024
Next Earnings (Confirmed): 8/06/2024
Dividend Payable: 9/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ZTS
CUSIP: 98978V10
CIK: 1555280
Web: www.zoetis.com
Phone: (973) 822-7000
Fax: 302-655-5049
Employees: 14,100
Year Founded: 2012

Price Target and Rating

Average Stock Price Target: $212.67
High Stock Price Target: $237.00
Low Stock Price Target: $180.00
Potential Upside/Downside: +17.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.19
Trailing P/E Ratio: 34.96
Forward P/E Ratio: 31.50
P/E Growth: 2.79
Net Income: $2.34 billion
Net Margins: 27.38%
Pretax Margin: 34.19%
Return on Equity: 50.34%
Return on Assets: 17.59%

Debt

Debt-to-Equity Ratio: 1.30
Current Ratio: 3.33
Quick Ratio: 1.94

Sales & Book Value

Annual Sales: $8.54 billion
Price / Sales: 9.69
Cash Flow: $6.48 per share
Price / Cash Flow: 27.98
Book Value: $10.87 per share
Price / Book: 16.69

Miscellaneous

Outstanding Shares: 456,300,000
Free Float: 455,565,000
Market Cap: $82.79 billion
Optionable: Optionable
Beta: 0.86

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Ms. Kristin C. Peck (Age 53)
CEO & Director
Comp: $3.54M
Mr. Wetteny N. Joseph (Age 52)
Executive VP & CFO
Comp: $1.6M
Ms. Wafaa Mamilli (Age 57)
EVP, Chief Digital & Tech. Officer, Group President for China, Brazil and Preci. Animal Health
Comp: $1.36M
Ms. Heidi C. Chen (Age 57)
Employee Advisor
Comp: $1.24M
Dr. Robert J. Polzer Ph.D. (Age 55)
Executive VP and President of Research & Development
Comp: $1.18M
Ms. Roxanne Lagano (Age 59)
EVP, Chief HR Officer & Global Operations, Interim General Counsel and Corporate Secretary
Mr. Steven Frank
Vice President of Investor Relations
Mr. William Price
VP & Chief Communications Officer
Ms. Jeannette Ferran Astorga (Age 49)
Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer
Mr. Nick Ashton (Age 51)
Executive VP and President of Global Manufacturing & Supply

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. reported a strong quarterly earnings performance, beating the consensus estimate by $0.04 per share. This indicates the company's ability to generate higher profits than expected, which can attract investors seeking growth opportunities.
The company has a healthy return on equity of 50.34%, showcasing efficient utilization of shareholder funds to generate earnings. A high return on equity is a positive indicator for investors as it signifies the company's profitability.
With a dividend yield of 0.99%, Zoetis offers investors a steady income stream through dividends. This can be appealing to income-oriented investors looking for consistent returns on their investment.
Despite a slight decrease in stock price recently, Zoetis has a strong market capitalization of $79.83 billion, indicating the company's significant presence and stability in the market. A large market cap can provide investors with confidence in the company's long-term prospects.
Analysts have maintained a positive outlook on Zoetis, with an average rating of "Buy" and an average price target of $211.75. This consensus among analysts can signal potential growth opportunities for investors.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

Corporate insiders own only 0.16% of the company's stock, indicating limited insider confidence in the company's future performance. Low insider ownership may raise concerns among investors about management's alignment with shareholder interests.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 22, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

ZTS Stock Analysis - Frequently Asked Questions

How have ZTS shares performed this year?: Zoetis' stock was trading at $197.37 on January 1st, 2024. Since then, ZTS stock has decreased by 8.9% and is now trading at $179.84.
View the best growth stocks for 2024 here.
How were Zoetis' earnings last quarter?: Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, May, 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. The firm's quarterly revenue was up 9.5% compared to the same quarter last year.
Read the conference call transcript.
What is Kristin Peck's approval rating as Zoetis' CEO?: 50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.
Does Zoetis have any subsidiaries?: Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and others.
Who are Zoetis' major shareholders?: Top institutional investors of Zoetis include Bank of New York Mellon Corp (1.03%), Banque Pictet & Cie SA (0.54%), Sarasin & Partners LLP (0.49%) and Swedbank AB (0.43%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed, Robert J Polzer, Glenn David, Roman Trawicki and Gregory Norden.
View institutional ownership trends.
How do I buy shares of Zoetis?: Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of Zoetis own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

This page (NYSE:ZTS) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Zoetis (ZTS) Stock Price, News & Analysis

Zoetis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio

About Zoetis Stock (NYSE:ZTS)

ZTS Stock Price History

ZTS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Cons

ZTS Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™